Conditional expression of the tumor suppressor p16 in a heterotopic glioblastoma model results in loss of pRB expression

Journal of Neuro-Oncology

Volumn 60, Issue 1, 2002, Pages 1-12

  Simon, Matthias ^a   Simon, Christian ^b   Köster, Gertraud ^a   Hans, Volkmar H J ^a   Schramm, Johannes ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Glioblastoma; p16; Tetracycline; Tumor model; Tumor suppression

Indexed keywords

DRINKING WATER; MONOCLONAL ANTIBODY KI 67; PROTEIN; PROTEIN P16; RETINOBLASTOMA PROTEIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE G1 PHASE; CLONOGENESIS; CONTROLLED STUDY; DATA ANALYSIS; EVIDENCE BASED MEDICINE; GENE THERAPY; GLIOBLASTOMA; GLIOMA; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INJECTION; LABELING INDEX; MORPHOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME;

ANIMALS; CELL CYCLE; CELL DIVISION; FUNGAL PROTEINS; GENES, P16; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; SERINE ENDOPEPTIDASES; TETRACYCLINE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036793067     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020226130478     Document Type: Article

References (46)

1. Zülch KJ: Brain Tumors. Their Biology and Pathology. 3rd edn. Springer, Berlin, Heidelberg, 1986
2. Floury A, Menegoz F, Grosclaude P, Daures JP, Henry-Amar M, Raverdy N, Schaffer P, Poisson M, Delattre J-Y: Descriptive epidemiology of cerebral gliomas in France. Cancer 79: 1195-1202, 1997
3. Davis FG, Freels S, Grutsch J, Barlas S, Brem S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88: 1-10, 1998
4. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994
5. Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A: Genomic structure, expression and mutational analysis of the p15 (MTS2) gene. Oncogene 11: 987-991, 1995
6. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW, Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358, 1994
7. Li Y-J, Hoang-Xuan K, Delattre J-Y, Poisson M, Thomas G, Hamelin R: Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 11: 597-600, 1995
8. Moulton T, Samara G, Chung W-Y, Yuan L, Desai R, Sisti M, Bruce J, Tycko B: MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146: 613-619, 1995
9. Schmidt EE, Ichimura K, Messerle KR, Goike HM, Collins VP: Infrequent methylation of CDKN2A (MTS1/p16) and rare mutations of both CDKN2A and CDKN2B (MTS2/p15) in primary astrocytic tumours. Br J Cancer 75: 2-8, 1997
10. ARF in 105 human primary gliomas. Oncogene 20: 1103-1109, 2001
11. Costello JF, Berger MS, Su Huang H-J, Cavenee WK: Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56: 2405-2410, 1996
12. ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11: 159-168, 2001
13. Bahuau M, Vidaud D, Jenkins RB, Bièche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela J-M, Harpey J-P, Caille B, Vidaud M: Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 58: 2298-2303, 1998
14. ARF but not CDKN2A in a melanoma - neural system tumour syndrome family. Hum Mol Genet 10: 55-62, 2001
15. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993
16. Shere CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60: 3689-3695, 2000
17. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1994
18. He J, Olson JJ, James CD: Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55: 4833-4836, 1995
19. Ichimura K, Schmidt EE, Goike HM, Collins VP: Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13: 1065-1072, 1996
20. Fuxe J, Akusjarvi G, Goike HM, Roos G, Collins VP, Pettersson RF: Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A. Cell Growth Differ 11: 373-384, 2000
21. Fueyo J, Gomez-Manzano C, Yung WKA, Clayman GL, Liu T-J, Bruner J, Levin VA, Kyritsis AP: Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12: 103-110, 1996
22. Costanzi-Strauss E, Strauss BE, Naviaux RK, Haas M: Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines. Exp Cell Res 238: 51-62, 1998
23. Lee SH, Kim MS, Kwon HC, Park IC, Park MJ, Lee CT, Kim YW, Kim CM, Hong SI: Growth inhibitory effect on glioma cells of adenovirus-mediated p16/INK4a gene transfer in vitro and in vivo. Int J Mol Med 6: 559-563, 2000
24. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WK, Sawaya R, Kyritsis AP, Rao JS: Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15: 2049-2057, 1997
25. Dirks PB, Patel K, Hubbard SL, Ackerley C, Hamel PA, Rutka JT: Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells. Oncogene 15: 2037-2048, 1997
26. Higashi H, Suzuki-Takahashi I, Yoshida E, Nishimura S, Kitagawa M: Expression of p16INK4a suppresses the unbounded and anchorage-independent growth of a glioblastoma cell line that lacks p16INK4a. Biochem Biophys Res Commun 231: 743-750, 1997
27. Uhrbom L, Nister M, Westermark B: Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene 15: 505-514, 1997
28. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Su Huang H-J: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55: 1351-1354, 1995
29. Tenan M, Benedetti S, Finocchiaro G: Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas. Biochem Biophys Res Commun 217: 195-202, 1995
30. Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JYJ, Su Huang H-J, Cavenee WK: Functional analysis of wild-type and malignant glioma derived CDKN2Aβ alleles: evidence for an RB-independent growth suppressive pathway. Oncogene 15: 2013-2020, 1997
31. Hama S, Sadatomo T, Yoshioka H, Kurisu K, Tahara E, Naruse I, Heike Y, Saijo N: Transformation of human glioma cell lines with the p16 gene inhibits cell proliferation. Anticancer Res 17: 1933-1938, 1997
32. Sawa H, Kamada H, Ohshima TA, Noguchi A, Itoh N, Saruta K, Hara M, Saito I: Exogenous expression of p16INK4a is associated with decrease in telomerase activity. J Neuro-Oncol 42: 45-57, 1999
33. ARF)/CDKN2B (p15) gene inactivation in malignant gliomas. Acta Neuropathol (Berl) 98: 444-452, 1999
34. Simon M, Köster G, Ludwig M, Mahlberg R, Rho S, Watzka M, Schramm J: Alternative splicing of the p15 CDK inhibitor in glioblastoma multiforme. Acta Neuropathol (Berl) 102: 167-174, 2001
35. Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551, 1992
36. Baron U, Bujard H: Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol 327: 401-421, 2000
37. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nature Med 3: 313-319, 1997
38. Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC: A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3: 229-235, 1993
39. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, De Tribolet N, Cavenee WK: Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649-652, 1994
40. Zheng C, Goldsmith CM, O'Connell BC, Baum BJ: Adenoviral vector cytotoxicity depends in part on the transgene encoded. Biochem Biophys Res Commun 274: 767-771, 2000
41. Thomas CE, Birkett D, Anozie I, Castro MG, Lowenstein PR: Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther 3: 36-46, 2001
42. Furth PA, St. Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard H, Henninghausen L: Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 91: 9302-9306, 1994
43. Hung KS, Hong CY, Lee J, Lin SK, Huang SC, Wang TM, Tse V, Sliverberg GD, Weng SC, Hsiao M: Expression of p16(INK4A) induces dominant suppression of glioblastoma growth in situ through necrosis and cell cycle arrest. Biochem Biophys Res Commun 269: 718-725, 2000
44. Ito M, Nagashima T, Hoshino T: Quantitation and distribution analysis of glial fibrillary acidic protein in human glioma cells in culture. J Neuropathol Exp Neurol 48: 560-567, 1989
45. Senner V, Sturm A, Hoess N, Wassmann H, Paulus W: In vivo glioma model enabling regulated gene expression. Acta Neuropathol (Berl) 99: 603-608, 2000
46. Fang X, Jin X, Xu HJ, Liu L, Peng HQ, Hong D, Roth JA, Yu Y, Xu F, Bast RC Jr, Mills GB: Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene 16: 1-8, 1998